The lab specialises in computational biology, functional genomics, and non-invasive diagnostics. With a focus on the computational and statistical analyses of the RNA, protein, and metabolites produced by healthy and unhealthy tissues/cell-types we define markers of various diseases that can be detected in blood, urine, and cerebrospinal fluid. We apply state-of-the-art statistical/machine-learning approaches and leverage the massive power and flexibility of cloud-computing to define novel biomarkers of cardiovascular disease, type 2 diabetes, neurodegenerative diseases, and various cancers. Recently the lab have become active contributors to Mass-General Brigham’s COVID-19 Innovation effort, helping to evaluate low-cost serologic (antibody/immunity) and diagnostic (viral RNA/protein detection) technologies before they are deployed to the greater Boston area and beyond.
Tools for processing exRNA and small-RNA-seq (exceRpt), and deep integration of RNA-seq and proteome data (EMpire)
Interactive apps including the COVID-19 prevalence app and the miRNA tissue atlas
APIs, including the miRNA tissue atlas as well as static data driving various publications
COVID-19 antibody test performance
In an effort to support the work evaluating technologies for serology (antibody) testing, the lab has developed an interactive webapp to explore the effect of changing prevalence on the population-level performance of these tests.